Answers are grounded in this paper and cite their sources.
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major cause of morbidity and mortality in patients with rheumatoid arthritis. This study evaluated the 1-year retention rates of Janus kinase (JAK) inhibitors in patients with RA-ILD and investigated their effects in experimental pulmonary fibrosis and human lung fibroblasts. One-year retention rates were assessed in patients with RA-ILD treated with baricitinib (BAR), peficitinib (PEF), filgotinib (FIL), upadacitinib, or tofacitinib. Pulmonary fibrosis was induced by bleomycin (BLM) in C57BL/6J mice, followed by treatment with BAR, PEF, or FIL. Survival, body weight, computed tomography findings, and histopathology were evaluated. Normal human lung fibroblasts (NHLFs) were stimulated with the interleukin (IL)-6/IL-6 receptor and treated with each JAK inhibitor. STAT1, STAT3, and STAT5 phosphorylation and the production of vascular endothelial growth factor (VEGF), transforming growth factor-β1, and fractalkine were assessed. JAK inhibitor 1-year retention rates did not differ significantly between patients with and without RA-ILD. In the BLM model, BAR attenuated pulmonary inflammation, preserved body weight, and improved survival compared with PEF and FIL. In NHLFs, BAR most effectively suppressed IL-6-induced STAT3 phosphorylation and VEGF production. These findings suggest that BAR may exert protective effects in experimental pulmonary fibrosis through suppression of the IL-6/STAT3/VEGF axis.
No takes yet. Share an insight, caveat, or question.
Kojima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: